Date: 2015-02-09
Type of information: Capital increase
Company: Innovacell (Austria)
Investors:
Amount: € 3 million
Funding type: capital increase
Planned used: This capital increase will further drive the clinical development of Innovacell\' cell therapies for the treatment of urinary and fecal incontinence, ICES 13 and ICEF 15. A phasee III trial is currently underway with ICES 13 and Innovacell expects to have the results of this study by the end of the year. Patients are now being recruited for the Phase II study of ICEF 15, the tissue therapy for targeted treatment of fecal incontinence. The company plans to have recruited all patients by the middle of the year. Early results are expected in the first quarter of 2016.
Others: * On February 9, 2015, Innovacell Biotechnologie AG, headquartered in Innsbruck, announced that the company has increased its capital by € 3 million.
Therapeutic area:
